PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34523052-7 2021 The intestinal injuries induced by CS were also attenuated by berberine, which was associated with inhibition of the production of systemic IL-6, IL-1beta, and TNF-alpha. Berberine 62-71 tumor necrosis factor Mus musculus 160-169 34867376-5 2021 Reduced expression levels of TNF-alpha, IL-1alpha, and C1qA were exhibited in the hippocampus of the berberine treatment group, and attenuated effect of declining neo-neuron, activation of microglia and astrocytes in the hippocampus of mice with sepsis were also found. Berberine 101-110 tumor necrosis factor Mus musculus 29-38 35428692-9 2022 injected with LPS, the increase of serum TNF-alpha and the drop of blood glucose were attenuated by berberine treatment. Berberine 100-109 tumor necrosis factor Mus musculus 41-50 35215376-6 2022 Additionally, pre-administration with BBR suppressed the expression of pro-inflammatory factors (interleukin (IL)-6, IL-1beta, cyclooxygenase (COX)-2 and tumor necrosis factor (TNF)-alpha) and the cell-proliferation marker Ki67, while expression of the tight junction proteins (ZO-1 and occludin) were increased in colon tissue. Berberine 38-41 tumor necrosis factor Mus musculus 154-187 34994821-8 2022 RESULTS: The results of this study demonstrated that berberine was able to protect remarkably the kidney from CP-induced injury through decreasing the level of BUN, Cr, NGAL, KIM-1, NO, MDA TNF-alpha, IL-1beta and increasing the level of GSH, CAT, SOD, and GPx activities. Berberine 53-62 tumor necrosis factor Mus musculus 190-199 33849702-3 2021 Moreover, berberine could protect the retinal morphology against the hyperglycemic insults and decrease glycogen accumulation, the contents of TNF-alpha and IL-1beta in the retinas, as demonstrated by HE staining, PAS staining and ELISA kits, respectively. Berberine 10-19 tumor necrosis factor Mus musculus 143-152 33307514-6 2021 Concomitant with enlarged colonic patches, the cultured colon of infected mice treated with berberine secreted significantly higher levels of interleukin-1beta (IL-1beta), IL-6, TNF-alpha, and CCL-2, while NLRP3 inhibitor MMC950 or knockout of NLRP3 gene abrogated berberine-induced hypertrophy of colonic patches, suggesting the involvement of the NLRP3 signaling pathway in this process. Berberine 92-101 tumor necrosis factor Mus musculus 178-187 33645072-21 2021 The mechanism may be related to the anti-inflammatory effect on UC mice by reducing the levels of IL-1beta, IL-6 and TNF-alpha in colon through limonin, palmatine and berberine regulating IL-17 signal pathway and TNF signal pathway via CASP3 and MMP9 meditated. Berberine 167-176 tumor necrosis factor Mus musculus 117-126 33645072-21 2021 The mechanism may be related to the anti-inflammatory effect on UC mice by reducing the levels of IL-1beta, IL-6 and TNF-alpha in colon through limonin, palmatine and berberine regulating IL-17 signal pathway and TNF signal pathway via CASP3 and MMP9 meditated. Berberine 167-176 tumor necrosis factor Mus musculus 117-120 33658925-8 2020 Subsequently, we revealed berberine suppressed the expression of pro-inflammatory factors including TNF-alpha and IL-6 through regulating PLA2G4A dysfunction in macrophage RAW 264.7 cells. Berberine 26-35 tumor necrosis factor Mus musculus 100-109 31642068-7 2020 Moreover, the expression level of YAP1 suppressed by TNF-alpha was reversed by berberine in concentration-dependent manner. Berberine 79-88 tumor necrosis factor Mus musculus 53-62 32194416-4 2020 In the current study, we found that BBR significantly decreased lipid accumulation, ameliorated reactive oxygen species (ROS) and lipid peroxides, Tumor necrosis factor alpha (TNF-alpha) expression, and phosphorylation of Nuclear factor kappa B (NF-kappaB) p65 both in vivo and in vitro. Berberine 36-39 tumor necrosis factor Mus musculus 147-174 32194416-4 2020 In the current study, we found that BBR significantly decreased lipid accumulation, ameliorated reactive oxygen species (ROS) and lipid peroxides, Tumor necrosis factor alpha (TNF-alpha) expression, and phosphorylation of Nuclear factor kappa B (NF-kappaB) p65 both in vivo and in vitro. Berberine 36-39 tumor necrosis factor Mus musculus 176-185 31306972-1 2019 To investigate effects of berberine exerts on A20 expression and regulation of intestinal epithelial tight junctions via the TNF-alpha-NF-kappaB-MLCK pathway in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D). Berberine 26-35 tumor necrosis factor Mus musculus 125-134 31306972-10 2019 Berberine downregulates abnormal activation of the TNF-alpha-NF-kappaB-MLCK pathway by upregulating expression of A20 in a mouse model of IBS-D, thereby protecting intestinal epithelial tight junctions and repairing the damage IBS-D causes to the intestinal epithelial barrier. Berberine 0-9 tumor necrosis factor Mus musculus 51-60 31337260-7 2019 Berberine inhibited the expression of pro-inflammatory cytokines including tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6), and interleukin-1beta (IL-1beta), along with inflammatory proteins including iNOS and COX-2. Berberine 0-9 tumor necrosis factor Mus musculus 75-108 30240693-1 2018 The current study was designed to explore the underlying therapeutic effect of berberine (BBR), an alkaloid compound against LPS (1 mug/ml)/TNFalpha (10 ng/ml) mediated apoptosis signal-regulating kinase 1 (ASK1) signaling in RAW 264.7 macrophages and adjuvant-induced arthritic synovial macrophages (AA-SM) with relation to miR-23a levels. Berberine 79-88 tumor necrosis factor Mus musculus 140-148 30240693-1 2018 The current study was designed to explore the underlying therapeutic effect of berberine (BBR), an alkaloid compound against LPS (1 mug/ml)/TNFalpha (10 ng/ml) mediated apoptosis signal-regulating kinase 1 (ASK1) signaling in RAW 264.7 macrophages and adjuvant-induced arthritic synovial macrophages (AA-SM) with relation to miR-23a levels. Berberine 90-93 tumor necrosis factor Mus musculus 140-148 29393413-6 2018 In vivo experiments showed that BBR treatment (5 mg/kg/day) significantly reduced the serum levels of visfatin, lipid, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), the protein expression of visfatin, p-p38 MAPK and p-c-Jun N-terminal kinase (JNK) in mice aorta and the distribution of visfatin in the atherosclerotic lesions in ApoE-/- mice fed with a Western diet. Berberine 32-35 tumor necrosis factor Mus musculus 144-171 29393413-6 2018 In vivo experiments showed that BBR treatment (5 mg/kg/day) significantly reduced the serum levels of visfatin, lipid, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), the protein expression of visfatin, p-p38 MAPK and p-c-Jun N-terminal kinase (JNK) in mice aorta and the distribution of visfatin in the atherosclerotic lesions in ApoE-/- mice fed with a Western diet. Berberine 32-35 tumor necrosis factor Mus musculus 173-182 29283990-9 2017 Serum levels of tumor necrosis factor (TNF)-alpha, interferon (IF)-gamma, interleukin (IL)-2, and IL-1beta were reduced by berberine pre-treatment; levels of serum IL-10, an anti-inflammatory cytokine, was elevated. Berberine 123-132 tumor necrosis factor Mus musculus 16-49 28759012-4 2017 A mechanistic study identified that these inhibitory effects of berberine occurred through blocking interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) expression in colonic macrophages. Berberine 64-73 tumor necrosis factor Mus musculus 125-152 28759012-4 2017 A mechanistic study identified that these inhibitory effects of berberine occurred through blocking interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) expression in colonic macrophages. Berberine 64-73 tumor necrosis factor Mus musculus 154-163 27832398-4 2017 In homogenized footpad tissue, the production of Th1-mediated cytokines including IFN-gamma, TNF-alpha, and IL-2 were suppressed following the administration of berberine. Berberine 161-170 tumor necrosis factor Mus musculus 93-102 27702567-9 2016 In addition, berberine reduced the elevated levels of serum TNF-alpha, IL-6 and MCP-1 and the expressions of TNF-alpha, IL-6 and MCP-1 and attenuated the phosphorylation of JNK and IKKbeta and the expression of NF-kappaB p65 in the obese adipose tissue, Raw264.7 macrophages and 3T3-L1 adipocytes, respectively. Berberine 13-22 tumor necrosis factor Mus musculus 60-69 27702567-9 2016 In addition, berberine reduced the elevated levels of serum TNF-alpha, IL-6 and MCP-1 and the expressions of TNF-alpha, IL-6 and MCP-1 and attenuated the phosphorylation of JNK and IKKbeta and the expression of NF-kappaB p65 in the obese adipose tissue, Raw264.7 macrophages and 3T3-L1 adipocytes, respectively. Berberine 13-22 tumor necrosis factor Mus musculus 109-118 27376853-12 2016 In line with the in vivo study, berberine treatment suppressed LPS-stimulated production of TNF-alpha and IL-1beta in BV2 cells. Berberine 32-41 tumor necrosis factor Mus musculus 92-101 27382358-3 2016 It was found berberine concentration-dependently induced the expressions of ATF-3 at the mRNA and protein levels and concomitantly suppressed the LPS-induced productions of proinflammatory cytokines (TNF-alpha, IL-6, and IL-1beta). Berberine 13-22 tumor necrosis factor Mus musculus 200-209 26642326-9 2015 Moreover, the addition of berberine to 5-ASA more significantly inhibited lymphocyte TNF-alpha secretion of DSS mice than 5-ASA alone. Berberine 26-35 tumor necrosis factor Mus musculus 85-94 24602493-9 2014 Furthermore, berberine could significantly suppressed the increasing expression of NF-kappaB, IL-6, TNFalpha, and IFNbeta in the RAW264.7 challenged with LPS. Berberine 13-22 tumor necrosis factor Mus musculus 100-108 25276218-4 2014 Among AC-mix ingredients, AA, CC, and their main constituents mangiferin and berberine potently inhibited the expression of proinflammatory cytokines TNF-alpha and IL-1beta, as well as the activation of NF-kappaB in LPS-stimulated peritoneal macrophages. Berberine 77-86 tumor necrosis factor Mus musculus 150-159 24188583-10 2013 BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells. Berberine 0-3 tumor necrosis factor Mus musculus 91-100 23734997-9 2013 The high-dose berberine (9 mg/kg) ameliorated oxidative stress, decreased TNF-alpha and TGF-beta1 expression, increased the levels of matrix metalloproteinase (MMP)-2, and stimulated the elimination of fibrous deposits. Berberine 14-23 tumor necrosis factor Mus musculus 74-83 22173918-9 2012 DSS-upregulated proinflammatory cytokine levels in the colon, including TNF, IFN-gamma, KC, and IL-17 were reduced by berberine. Berberine 118-127 tumor necrosis factor Mus musculus 72-75 22145808-5 2012 Berberine, at 10 mg/kg body weight, showed significant inhibition in tumor-directed capillary formation and in various proangiogenic factors, such as vascular endothelial growth factor (VEGF), and proinflammatory mediators, such as interleukin (IL)-1beta, IL-6, tumor necrosis factor alpha (TNF-alpha), and granulocyte macrophage colony-stimulating factor (GM-CSF), which are involved in tumor angiogenesis. Berberine 0-9 tumor necrosis factor Mus musculus 262-289 22145808-5 2012 Berberine, at 10 mg/kg body weight, showed significant inhibition in tumor-directed capillary formation and in various proangiogenic factors, such as vascular endothelial growth factor (VEGF), and proinflammatory mediators, such as interleukin (IL)-1beta, IL-6, tumor necrosis factor alpha (TNF-alpha), and granulocyte macrophage colony-stimulating factor (GM-CSF), which are involved in tumor angiogenesis. Berberine 0-9 tumor necrosis factor Mus musculus 291-300 23087140-5 2012 RESULTS: Berberine pretreatment reduced the expression of hepatic PCSK9, decreased the plasma TC, TG, LDL-C, IFNgamma, TNFalpha, IL-1alpha, and 8-isoprostane concentrations; increased HDL-C level and LDLR expression in mice. Berberine 9-18 tumor necrosis factor Mus musculus 119-127 21095217-0 2011 Hepatoprotective activity of berberine is mediated by inhibition of TNF-alpha, COX-2, and iNOS expression in CCl(4)-intoxicated mice. Berberine 29-38 tumor necrosis factor Mus musculus 68-77 21095217-6 2011 Histopathological changes were reduced and the expression of tumor necrosis factor-alpha (TNF-alpha), cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) was markedly attenuated by berberine 10mg/mg. Berberine 198-207 tumor necrosis factor Mus musculus 61-88 21095217-6 2011 Histopathological changes were reduced and the expression of tumor necrosis factor-alpha (TNF-alpha), cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) was markedly attenuated by berberine 10mg/mg. Berberine 198-207 tumor necrosis factor Mus musculus 90-99 20868663-3 2010 Berberine promoted differentiation and inhibited lipid accumulation of 3T3-L1 cells, further decreased PPARalpha/delta/gamma, CDK9 and cyclin T1 mRNA and protein expression and decreased tumor necrosis factor alpha content in supernatants of both control and RNA interference-treated 3T3-L1 cells. Berberine 0-9 tumor necrosis factor Mus musculus 187-214 20828550-5 2010 Berberine inhibited colonic expression of iNOS, COX-2, IL-1beta, IL-6, and TNF-alpha, but increased IL-10 expression in the colons of TNBS-treated C3H/HeN and C3H/HeJ mice. Berberine 0-9 tumor necrosis factor Mus musculus 75-84 20512929-7 2010 In addition, berberine effectively inhibited proinflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6 expression. Berberine 13-22 tumor necrosis factor Mus musculus 79-88 20822024-1 2010 OBJECTIVE: To investigate the effect of berberine on serum levels of TNF-alpha, IL-6 and adiponectin in obese mice induced by high fat diet and its potential molecular mechanisms. Berberine 40-49 tumor necrosis factor Mus musculus 69-78 20822024-11 2010 After two-week treatment of berberine, serum levels of TNF-alpha, IL-6 in BL and BH were lower than those in BM (P < 0.05, respectively). Berberine 28-37 tumor necrosis factor Mus musculus 55-64 16923341-6 2006 The administration of berberine significantly reduced plasma TNF-alpha, IFN- gamma, and NO levels, but did not suppress plasma IL-12 levels in mice exposed to LPS. Berberine 22-31 tumor necrosis factor Mus musculus 61-70 16391493-6 2006 RESULTS: Berberine dose-dependently inhibited IL-8 mRNA and MCP-1 mRNA expression of the cells and protein levels in the media stimulated with IL-1beta or TNF-alpha. Berberine 9-18 tumor necrosis factor Mus musculus 155-164